Functional annotation of the 2q35 breast cancer risk locus implicates a structural variant in influencing activity of a long-range enhancer element.
Breast Neoplasms
/ genetics
CRISPR-Cas Systems
Cell Line
Chromosome Mapping
Chromosomes, Human, Pair 2
Female
Genetic Association Studies
Genetic Variation
Humans
Insulin-Like Growth Factor Binding Protein 5
/ genetics
Molecular Sequence Annotation
Promoter Regions, Genetic
Risk Factors
Sequence Deletion
breast cancer risk
functional annotation
risk locus
Journal
American journal of human genetics
ISSN: 1537-6605
Titre abrégé: Am J Hum Genet
Pays: United States
ID NLM: 0370475
Informations de publication
Date de publication:
01 07 2021
01 07 2021
Historique:
received:
20
10
2020
accepted:
25
05
2021
pubmed:
20
6
2021
medline:
1
9
2021
entrez:
19
6
2021
Statut:
ppublish
Résumé
A combination of genetic and functional approaches has identified three independent breast cancer risk loci at 2q35. A recent fine-scale mapping analysis to refine these associations resulted in 1 (signal 1), 5 (signal 2), and 42 (signal 3) credible causal variants at these loci. We used publicly available in silico DNase I and ChIP-seq data with in vitro reporter gene and CRISPR assays to annotate signals 2 and 3. We identified putative regulatory elements that enhanced cell-type-specific transcription from the IGFBP5 promoter at both signals (30- to 40-fold increased expression by the putative regulatory element at signal 2, 2- to 3-fold by the putative regulatory element at signal 3). We further identified one of the five credible causal variants at signal 2, a 1.4 kb deletion (esv3594306), as the likely causal variant; the deletion allele of this variant was associated with an average additional increase in IGFBP5 expression of 1.3-fold (MCF-7) and 2.2-fold (T-47D). We propose a model in which the deletion allele of esv3594306 juxtaposes two transcription factor binding regions (annotated by estrogen receptor alpha ChIP-seq peaks) to generate a single extended regulatory element. This regulatory element increases cell-type-specific expression of the tumor suppressor gene IGFBP5 and, thereby, reduces risk of estrogen receptor-positive breast cancer (odds ratio = 0.77, 95% CI 0.74-0.81, p = 3.1 × 10
Identifiants
pubmed: 34146516
pii: S0002-9297(21)00218-4
doi: 10.1016/j.ajhg.2021.05.013
pmc: PMC8322933
pii:
doi:
Substances chimiques
IGFBP5 protein, human
0
Insulin-Like Growth Factor Binding Protein 5
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1190-1203Subventions
Organisme : Wellcome Trust
ID : 203477/Z/16/Z
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_UU_00004/01
Pays : United Kingdom
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Informations de copyright
Copyright © 2021 The Authors. Published by Elsevier Inc. All rights reserved.
Références
Nat Genet. 2013 Apr;45(4):392-8, 398e1-2
pubmed: 23535733
Nat Genet. 2017 Dec;49(12):1767-1778
pubmed: 29058716
Nat Commun. 2016 Sep 07;7:12675
pubmed: 27601076
J Intern Med. 2013 Nov;274(5):414-24
pubmed: 24127939
Int J Cancer. 2016 Sep 15;139(6):1303-1317
pubmed: 27087578
Genome Res. 2014 Nov;24(11):1854-68
pubmed: 25122612
Cell. 2014 Oct 9;159(2):358-73
pubmed: 25303530
Am J Hum Genet. 2015 Jan 8;96(1):5-20
pubmed: 25529635
Science. 2013 Mar 1;339(6123):1074-7
pubmed: 23328393
PLoS Genet. 2014 Oct 30;10(10):e1004722
pubmed: 25357204
Am J Hum Genet. 2016 Oct 6;99(4):903-911
pubmed: 27640304
Genomics. 2015 Sep;106(3):159-164
pubmed: 26072433
Science. 2016 Nov 11;354(6313):769-773
pubmed: 27708057
Nat Genet. 2013 Apr;45(4):353-61, 361e1-2
pubmed: 23535729
Nat Genet. 2020 Jan;52(1):56-73
pubmed: 31911677
Nat Commun. 2014 Sep 23;4:4999
pubmed: 25248036
Am J Hum Genet. 2013 Dec 5;93(6):1046-60
pubmed: 24290378
Nat Genet. 2013 Apr;45(4):371-84, 384e1-2
pubmed: 23535731
Nat Genet. 2016 Apr;48(4):374-86
pubmed: 26928228
Nat Commun. 2018 Mar 12;9(1):1028
pubmed: 29531215
Hum Mol Genet. 2016 Sep 1;25(17):3863-3876
pubmed: 27402876
PLoS Genet. 2019 Dec 27;15(12):e1008501
pubmed: 31881017
Hum Mol Genet. 2015 May 15;24(10):2966-84
pubmed: 25652398
Mol Cell. 2013 Oct 10;52(1):25-36
pubmed: 24076218
Hum Mol Genet. 2015 Jan 1;24(1):285-98
pubmed: 25168388
PLoS One. 2016 Aug 24;11(8):e0160316
pubmed: 27556229
Nature. 2012 Sep 6;489(7414):75-82
pubmed: 22955617
Nature. 2012 Sep 6;489(7414):57-74
pubmed: 22955616
Cell. 2013 Jul 18;154(2):442-51
pubmed: 23849981
Nat Protoc. 2020 Aug;15(8):2387-2412
pubmed: 32641802
Nat Genet. 2007 Jul;39(7):865-9
pubmed: 17529974
Br J Cancer. 2011 Sep 27;105(7):911-7
pubmed: 21897394
Nat Genet. 2020 Jun;52(6):572-581
pubmed: 32424353
Breast Cancer Res. 2016 Jun 21;18(1):64
pubmed: 27459855
Nat Commun. 2020 Dec 8;11(1):6283
pubmed: 33293539
Nat Protoc. 2013 Nov;8(11):2281-2308
pubmed: 24157548
Nature. 2017 Nov 2;551(7678):92-94
pubmed: 29059683
Am J Hum Genet. 2013 Apr 4;92(4):489-503
pubmed: 23540573
Cancer Epidemiol Biomarkers Prev. 2015 Nov;24(11):1680-91
pubmed: 26354892
Am J Hum Genet. 2017 Aug 3;101(2):255-266
pubmed: 28777932
Nature. 2013 Jun 27;498(7455):516-20
pubmed: 23728302
Am J Hum Genet. 2015 Jul 2;97(1):22-34
pubmed: 26073781